MALT1 is activated by doxorubicin and mediates therapy resistance in triple-negative breast cancer

被引：0
|
作者：
Beecher, Maria
Hu, Dong
Klei, Linda
Little, Jack
McAllister-Lucas, Linda M.
Lucas, Peter C.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1762
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1762
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
    Lee, Jia-Ying Lloyd
    Ekambaram, Prasanna
    Carleton, Neil M.
    Hu, Dong
    Klei, Linda R.
    Cai, Zongyou
    Myers, Max, I
    Hubel, Nathaniel E.
    Covic, Lidija
    Agnihotri, Sameer
    Krappmann, Daniel
    Bornancin, Frederic
    Lee, Adrian, V
    Oesterreich, Steffi
    McAllister-Lucas, Linda M.
    Lucas, Peter C.
    MOLECULAR CANCER RESEARCH, 2022, 20 (03) : 373 - 386
  • [2] Macropinocytosis mediates resistance to loss of glutamine transport in triple-negative breast cancer
    Kanu Wahi
    Natasha Freidman
    Qian Wang
    Michelle Devadason
    Lake-Ee Quek
    Angel Pang
    Larissa Lloyd
    Mark Larance
    Fabio Zanini
    Kate Harvey
    Sandra O’Toole
    Yi Fang Guan
    Jeff Holst
    The EMBO Journal, 2024, 43 (23) : 5857 - 5882
  • [3] The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
    Tormo, Eduardo
    Ballester, Sandra
    Adam-Artigues, Anna
    Burgues, Octavio
    Alonso, Elisa
    Bermejo, Begona
    Menendez, Silvia
    Zazo, Sandra
    Madoz-Gurpide, Juan
    Rovira, Ana
    Albanell, Joan
    Rojo, Federico
    Lluch, Ana
    Eroles, Pilar
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [4] The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
    Eduardo Tormo
    Sandra Ballester
    Anna Adam-Artigues
    Octavio Burgués
    Elisa Alonso
    Begoña Bermejo
    Silvia Menéndez
    Sandra Zazo
    Juan Madoz-Gúrpide
    Ana Rovira
    Joan Albanell
    Federico Rojo
    Ana Lluch
    Pilar Eroles
    Scientific Reports, 9
  • [5] New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin
    Cristina Alexandra Ciocan-Cȃrtiţă
    Ancuţa Jurj
    Lajos Raduly
    Roxana Cojocneanu
    Alin Moldovan
    Valentina Pileczki
    Laura-Ancuta Pop
    Liviuţa Budişan
    Cornelia Braicu
    Schuyler S. Korban
    Ioana Berindan-Neagoe
    Molecular and Cellular Biochemistry, 2020, 475 : 285 - 299
  • [6] New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin
    Ciocan-Cartita, Cristina Alexandra
    Jurj, Ancuta
    Raduly, Lajos
    Cojocneanu, Roxana
    Moldovan, Alin
    Pileczki, Valentina
    Pop, Laura-Ancuta
    Budisan, Liviuta
    Braicu, Cornelia
    Korban, Schuyler S.
    Berindan-Neagoe, Ioana
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2020, 475 (1-2) : 285 - 299
  • [7] Macropinocytosis mediates metabolic resistance to loss of glutamine transport in triple-negative breast cancer
    Wahi, Kanu
    Freidman, Natasha
    Wang, Qian
    Guan, Yi Fang
    Holst, Jeff
    CANCER RESEARCH, 2024, 84 (03)
  • [8] HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer
    Lanjing Wei
    Sung Hae Kim
    Ahlam M. Armaly
    Jeffrey Aubé
    Liang Xu
    Xiaoqing Wu
    npj Precision Oncology, 8 (1)
  • [9] Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
    Lev, Sima
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2020, 48 (02) : 657 - 665
  • [10] Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial
    Loap, Pierre
    Loirat, Delphine
    Berger, Frederique
    Rodrigues, Manuel
    Bazire, Louis
    Pierga, Jean-Yves
    Vincent-Salomon, Anne
    Laki, Fatima
    Boudali, Latifa
    Raizonville, Laurence
    Mosseri, Veronique
    Jochem, Anne
    Eeckhoutte, Alexandre
    Diallo, Mamadou
    Stern, Marc-Henri
    Fourquet, Alain
    Kirova, Youlia
    JAMA ONCOLOGY, 2022, 8 (12) : 1802 - 1808
12345